Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pediatric Exclusivity Bill Passes; CBO Scoring Flawed, Rep. Tauzin Says

This article was originally published in The Tan Sheet

Executive Summary

Thirty to 50 pediatric studies of generic drugs would be funded by the National Institutes of Health over the next five years under HR 2887, House Energy & Commerce Committee Chairman Billy Tauzin (R-La.) estimated

You may also be interested in...



Pediatric Study Royalty Fund Would Be Created By Wellstone Amendment

Drug companies would be required to set aside a portion of product sales to fund pediatric research for off-patent drugs under an amendment Sen. Paul Wellstone (D-Minn.) will offer to the pediatric exclusivity reauthorization bill when it is considered on the Senate floor.

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Topics

UsernamePublicRestriction

Register

PS093315

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel